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Abstract
A major problem in cancer treatment is the development of resistance to multiple 
chemotherapeutic agents in tumor cells. A major mechanism of this multidrug resistance (MDR) is 
overexpression of the MDR1 product P-glycoprotein, known to bind to and transport a wide 
variety of agents. This review concentrates on the progress made toward understanding the role of 
this protein in MDR, identifying and characterizing the drug binding sites of P-glycoprotein, and 
modulating MDR by P-glycoprotein-specific inhibitors. Since our initial discovery that P-
glycoprotein binds to vinblastine photoaffinity analogs, many P-glycoprotein-specific 
photoaffinity analogs have been developed and used to identify the particular domains of P-
glycoprotein capable of interacting with these analogs and other P-glycoprotein substrates. 
Furthermore, significant advances have been made in delineating the drug binding sites of this 
protein by studying mutant P-glycoprotein. Photoaffinity labeling experiments and the use of site-
directed antibodies to several domains of this protein have allowed the localization of the general 
binding domains of some of the cytotoxic agents and MDR modulators on P-glycoprotein. 
Moreover, site-directed mutagenesis studies have identified the amino acids critical for the binding 
of some of these agents to P-glycoprotein. Furthermore, equilibrium binding assays using plasma 
membranes from MDR cells and radioactive drugs have aided our understanding of the modes of 
drug interactions with P-glycoprotein. Based on the available data, a topological model of P-
glycoprotein and the approximate locations of its drug binding sites, as well as a proposed 
classification of multiple drug binding sites of this protein, is presented in this review.
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INTRODUCTION
Most metastatic cancers, as well as some hematological malignancies, are either intrinsically 
resistant to chemotherapy or acquire drug resistance subsequent to chemotherapy. Therefore, 
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a major obstacle in cancer chemotherapy is the development of resistance to 
chemotherapeutic agents in tumor cells. It is well documented that several members of the 
large family of ABC transporters confer multidrug resistance (MDR) in human cancer cells. 
These transporters are three types of drug efflux pumps: the multidrug resistance gene 1 
(MDR1 or ABCB1)-encoded P-glycoprotein, the multidrug resistance-associated protein 
(MRP1 or ABCC1), and breast cancer resistance protein (BCRP or ABCG2) [1–7]. These 
proteins may play an important part in the intrinsic or acquired defense of cells against a 
wide variety of drugs [1–7]. Recent studies have also shown the broad tissue distribution and 
drug substrate specificity of the seven MRP family members (MRP1-7; or ABCC1-6 and 
ABCC10) [3–5]. MRPs are multispecific organic anion transporters, which can transport 
negatively charged anionic drugs and neutral drugs conjugated to glutathione, glucuronate or 
sulfate [3–5]. However, the MDR1 P-glycoprotein transports a broad range of unmodified 
lipophilic agents, including a wide variety of drugs with different cellular targets, and 
confers resistance to such drugs by decreasing their intracellular concentrations [8, 9]. 
Furthermore, P-glycoprotein is involved in limiting the oral bioavailability and tissue 
penetration of a variety of structurally divergent molecules. This review will concentrate on 
advances made over the last two decades in understanding the functional role of P-
glycoprotein; identifying, characterizing, and localizing the drug-binding sites of P-
glycoprotein structure; and applying this knowledge to identify potent P-glycoprotein-
specific MDR modulators.
P-GLYCOPROTEIN AND MDR
Mammalian P-glycoprotein is encoded by a multigene family and divided into three classes: 
class I and II P-glycoproteins, which confer drug resistance, and class III, which does not 
[10]. The human class I P-glycoprotein encoded by the MDR1 gene transports xenobiotics 
[9, 11], HIV protease inhibitors [12], steroids [13], immunosuppressants [14, 15], calcium 
cannel blockers [16], dopamine antagonists [17], peptides [18], phospholipids [19], and 
cholesterol [20]. In addition to increased expression during development of the MDR 
phenotype, P-glycoprotein is differentially expressed in normal tissues. We originally 
suggested that P-glycoprotein serves as an anti-apoptotic protein [21]. More recent reports 
have shown that in addition to its role in inducing resistance to anticancer agents, P-
glycoprotein plays a general anti-apoptotic role, since cells overexpressing P-glycoprotein 
are resistant to a variety of apoptotic stimuli including serum starvation, Fas ligand, tumor 
necrosis factor, and UV-irradiation [22–28]. It is clear that P-glycoprotein has diverse 
functions in different cells and tissues; therefore, its expression is complex and highly 
regulated.
A very important concern in the treatment of human malignancies is intrinsic or acquired 
resistance to chemotherapy. Several reports have shown that overexpression of the MDR1 
gene is a negative prognostic factor in some solid tumors [29–33]. Recent results by 
Abolhoda et al. [32] clearly demonstrated rapid activation of MDR1 gene expression in 
human metastatic sarcoma after in vivo exposure to doxorubicin. This latter study is 
particularly significant because it is the first analysis of transient induction of P-glycoprotein 
in solid tumors. One of the major limitations in the design of clinical trials correlating P-
glycoprotein expression with the outcome of chemotherapy has been the time lag between 
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the administration of chemotherapy and the determination of P-glycoprotein status. The best 
correlation between P-glycoprotein expression and unresponsiveness to chemotherapy has 
been demonstrated in hematological malignancies. These include acute myelogenous and 
lymphocytic leukemias (AML and ALL), multiple myeloma and non-Hodgkin's lymphoma 
[34]. Moreover, clinical studies have shown that the expression of P-glycoprotein in AML is 
a negative prognostic feature, particularly in the elderly [34–38]. Moreover, it has also been 
shown that overexpression of P-glycoprotein in hematological malignancies occurs more 
frequently at relapse than upon initial presentation [39].
P-GP STRUCTURE AND FUNCTION
The human P-glycoprotein is a 1280 amino acid membrane protein that confers resistance to 
a wide variety of structurally diverse anticancer agents by adenosine triphosphate (ATP)-
dependent efflux of these drugs across the plasma membrane [40–43]. This multidrug 
transporter is composed of two cassettes, and based on hydropathy plot analysis, each of the 
P-glycoprotein cassettes contain six putative transmembrane (TM) segments followed by a 
consensus nucleotide-binding domain (NBD). The two homologous cassettes are separated 
by an intracellular linker region of about 60 amino acid residues [40–44]. In addition to this 
model of P-glycoprotein, another model has been proposed, which consists of two 
membrane-embedded sixteen-strand β-barrels, connected by short loops to two six-helix 
bundles beneath each barrel [45, 46]. The involvement of TM segments and NBDs in 
substrate recognition and ATP binding/hydrolysis, respectively, have been established [47–
52]. Substantial biochemical evidence, including changes in drug binding, epitope 
accessibility, fluorescent and spectroscopic measurements, and protease susceptibility [53–
59], suggests that TM segments undergo conformational change upon nucleotide binding. P-
glycoprotein has high basal ATPase activity, and its ATPase activity can also be stimulated 
by drug binding [60–63]. in each cycle of ATP binding and hydrolysis, at least four 
conformations of P-glycoprotein (ligand-free, ATP-bound, ADP/Pi-bound after ATP 
hydrolysis, and ADP-bound) have been demonstrated [57]. Vanadate (V) can inhibit the 
drug (substrate)-inducible ATPase activity of P-glycoprotein by stably trapping the 
nucleoside diphosphate in the P-glycoprotein-ADP-bound/V conformation [64]. During the 
catalytic cycle of P-glycoprotein, although the transition state (P-ADP/Pi-bound/V) can be 
generated both via the hydrolysis of ATP and by directly providing ADP to the system, in 
the presence of substrate, the reaction is driven toward hydrolysis of ATP. Mechanistic 
details of the ATP hydrolytic cycle of MDR1 have significantly progressed over the last few 
years, and in the current model, both NBD's catalytic sites in MDR1 are active and ATP is 
hydrolyzed alternatively within the two sites. ATP hydrolysis at one site triggers 
conformational changes within P-glycoprotein resulting in drug transport, while at the other 
site, hydrolysis of a second ATP molecule is required for resetting the initial or high-affinity 
binding conformation. The two active sites act in a cooperative manner, and experiments 
support a model where the two ATP binding domains form a coupled catalytic machinery 
[65–67]. Recent evidence suggests that drugs alter the binding affinity to favor association 
of ATP with P-glycoprotein at the beginning of the catalytic cycle of the transport, and 
release of ADP from the transition state following nucleotide hydrolysis [68].
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To understand the details of P-glycoprotein function, Rosenberg et al. [69, 70] reported the 
low to medium resolution structure of P-glycoprotein by single particle image analysis and 
electron crystallography of 2-dimensional (2-D) crystals. The 2-D projection maps of P-
glycoprotein trapped at different stages of the hydrolytic cycle suggested that the TM 
segments form a chamber within the membrane that seems to be open to the extracellular 
milieu, and may also be accessible from the lipid phase at the interfaces between the two 
TM segments. These studies conclude that (1) nucleotide binding to P-glycoprotein causes a 
repacking of the TM segments and decreased drug binding affinity, therefore, ATP binding, 
not hydrolysis, drives the major conformational change associated with substrate 
translocation by P-glycoprotein, and (2) the distinct conformation of the protein was 
observed in the post-hydrolytic transition state prior to the release of ADP/P(i). The 
biochemical results suggest that these rearrangements may involve rotation of TM α-helices. 
These data are consistent with the recent results, comparing the 3-D structure of P-
glycoprotein in the presence and absence of nucleotide. The results show that upon 
nucleotide binding, substantial conformational changes throughout the TM segments of P-
glycoprotein occur, which require significant repacking of the transmembrane helices and 
opening a central pore along its length, potentially facilitating the transport of hydrophobic 
compounds from the lipid bilayer of the plasma membrane to the aqueous pore of the 
transporter.
Much effort has focused on identifying P-glycoprotein-specific pharmacological inhibitors 
to circumvent MDR. Several generations of P-glycoprotein-specific inhibitors have been 
developed to reverse P-glycoprotein-mediated MDR [71–74]. However, the major question 
is how P-glycoprotein interacts with such a large and diverse number of compounds. To 
answer this question, over the last several years, a major focus of research in many 
laboratories has been evaluating the functional role of P-glycoprotein as mediator of the 
MDR phenotype and its reversal by chemosensitizers (MDR modulators). In determining the 
biochemical basis of MDR, investigators have examined the relationship of P-glycoprotein 
drug-binding specificity to particular MDR phenotypic properties, such as drug uptake, 
efflux, accumulation, and MDR specificity. However, the molecular architecture of the drug 
binding sites, their exact location on the P-glycoprotein molecule, and the total number of 
the drug binding sites remain to be determined. Delineating the architecture of the drug 
binding sites of P-glycoprotein for both cytotoxic agents and the MDR modulators will be 
invaluable not only to understand how drugs interact with this protein, but also to design 
more useful and specific inhibitors of P-glycoprotein function. To identify and characterize 
P-glycoprotein drug-binding sites, several approaches have been employed including (1) 
equilibrium binding assays using radiolabeled P-glycoprotein-specific substrate and plasma 
membranes from drug resistant cells, (2) photoaffinity labeling experiments using 
photoaffinity analogs of both MDR-related agents and MDR modulators and P-
glycoprotein-bearing cells or their plasma membranes, and (3) studying the naturally 
occurring mutant P-glycoproteins or site-directed mutations in the MDR1 gene, and analysis 
of the mutant P-glycoproteins with respect to their drug transport, drug binding and ATP 
hydrolysis capacity in the transfected cell lines compared to the wild-type protein.
Safa Page 4
Curr Med Chem Anticancer Agents. Author manuscript; available in PMC 2015 May 28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
PHOTOAFFINITY LABELING OF P-GP
A. Photoactive Analogs of Cytotoxic Agents
While significant advances have been made in delineating the molecular mechanism of drug 
transport by P-glycoprotein, it is important to understand how the protein can bind to 
structurally diverse anticancer drugs, and to localize these sites and determine their 
relationship to the modulator binding sites. Over the last several years, a major focus of 
research in many laboratories has been to evaluate the functional role of P-glycoprotein as a 
mediator of the MDR phenotype and its reversal by modulators. The synthesis and use of 
radiolabeled photoactive analogs of cytotoxic agents and MDR modulators [75, 76] has 
allowed the identification of P-glycoprotein as a specific multidrug acceptor, thereby aiding 
our understanding of the functional role of this protein in MDR and its possible involvement 
in MDR reversal by P-glycoprotein modulators.
We initially explored the function of P-glycoprotein by synthesizing and using two 
photoaffinity analogs of vinblastine, one labeled with 3H and one with 125I [76]. Detailed 
procedures for the synthesis and use of these photoaffinity analogs as well as photoaffinity 
analogs of several cytotoxic agents and MDR modulators were recently published [75]. The 
structure of the vinblastine radioiodinated photoaffinity derivative N-(p-azido-
[3-125I]salicyl)-N'-aminoethylvindesine ([125I]NASV) [76] is presented in Fig. (1). Purified 
plasma membranes, mixed membranes vesicles, or intact cells were incubated with 
[125I]NASV at 25°C for 15 min and then irradiated at 302 nm for [3H] NABV, or 366 nm 
for [125I]NASV, for 20 min to activate the analog. Polyacrylamide gel electrophoresis of 
solubilized photoaffinity labeled samples followed by autoradiography showed that 
[125I]NASV specifically bound only to P-glycoprotein in MDR cell lines [10, 77–80] (Fig. 
2A and B). Specific interaction of [125I]NASV with P-glycoprotein in the MDR variants of 
the human lymphoblastic leukemia cell line CEM expressing 100-, 1000- and 5000-fold 
resistance to vinblastine (CEM/VBL100, CEM/VBL1000, and CEM/VBL5000) is shown in 
Fig, (2A). Evidence for the multidrug specificity of the Vinca alkaloid-binding site of P-
glycoprotein has also been obtained [75, 79]. In the presence of 100 μM of vinblastine, 
[125I]NASV photolabeling of P-glycoprotein in KB-3-1 epidermoid carcinoma cell line 
transfected with the MDR1 gene (KB-GRC1 transfectants) was totally inhibited (Fig. 2B). 
Moreover, dactinomycin (actinomycin D), or doxorubicin partially inhibited [125I]NASV 
photolabeling of P-glycoprotein in these cells (Fig. 2B). In contrast, colchicine, a drug to 
which the MDR cells are also cross-resistant, and methotrexate, a drug to which the MDR 
cells are sensitive, do not block vinblastine photolabeling of P-glycoprotein (Fig. 2B), 
suggesting that either colchicine binds to a separate site, or that it has lower affinity for the 
vinblastine binding site of P-glycoprotein. Similar results were obtained when other MDR 
cell lines were used in [125I]NASV photolabeling experiments [10].
Since the original synthesis of the photoaffinity analogs of vinblastine, a number of 
photoaffinity analogs of MDR-related drugs have been synthesized [76]. Anthracyclines 
were poor inhibitors of P-glycoprotein photoaffinity labeling with the vinblastine 
photoaffinity analog (Fig. 2A) [79], suggesting that anthracyclines and Vinca alkaloids 
either have different binding affinities or separate binding sites on P-glycoprotein. 
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Originally, Bushe et al. [81] demonstrated that high specific activity [125I]iodomycin, a 
Bolton-Hunter derivative of daunorubicin, which like daunorubicin is an inherently 
photoactive compound, can bind specifically to P-glycoprotein. The binding of 
[125I]iodomycin was inhibited by vinblastine > daunorubicin > colchicine [81]. We [10, 80] 
and others [82] have also used a 3H-labeled azidobenzoyl derivative of daunorubicin, N-(p-
azido-[3, 5-3H]benzoyl) daunorubicin ([3H]NABD) (Fig. 1). We also have synthesized a 
tritiated photoaffinity analog of doxorubicin, N-(p-azido-[3, 5-3H] benzoyl)doxorubicin 
([3H]NAB-DOX) and a radioiodinated photoaffinity analog of daunorubicin, N-(p-azido-
[3-125I] salicyl)daunorubicin ([125I]NAS-DNR) (Fig. 1), and found that these analogs bind 
specifically to P-glycoproteina [80]. Photolabeling of P-glycoprotein with [3H]NAB-DOX 
was inhibited by cyclosporin A > vinblastine > NAB-DOX > and doxorubicin, respectively. 
Using [125I]NAS-DNR (Fig. 1), we have provided the first experimental confirmation that 
an amine group at C-3' is an important structural element of anthracyclines recognized by P-
glycoprotein and that the hydroxyl group at C-14 (Fig. 1) might significantly affect the 
binding affinities of anthracyclines to P-glycoproteina.
While colchicine did not inhibit the binding of [125I]NASV (Fig. 2B), it is transported by P-
glycoprotein [76, 79]. To determine whether P-glycoprotein binds colchicines, we 
synthesized and used photoactive analogs of colchicine [83]. Both 3H-and 125I-labeled 
photoaffinity analogs bound specifically to P-glycoprotein [83]. The structure of the 125I-
labeled photoaffinity analog N-(p-azido-3-125I-salicyl)-aminohexanoyldiacetylcolchicine 
([125I]NASC) is shown in Fig. (1). Photolabeling of P-glycoprotein by [125I]NASC was 
inhibited by other compounds to which MDR cells are resistant in the following order: 
vinblastine > vincristine > doxorubicin > dactinomycin (actinomycin D) > colchicine [83]. 
These results and photoaffinity labeling experiments with [125I]NASV [18] and Fig. (2) 
suggest that vinblastine and colchicine may bind to separate sites, or that P-glycoprotein 
may have a common drug-acceptor site displaying high affinity for Vinca alkaloids and 
lower affinity for colchicine.
Photoactive analogs of other MDR-related drugs including rhodamine 123 (Rh 123), 125I-
labeled azidosalicyclic acid (ASA)-Rh 123 ([125I]ASA-Rh 123) and benzimidazole (BZ) 
([125I]ASA-BZ) (Fig. 1) have also been shown to specifically photolabel P-glycoprotein [84, 
85]. Interestingly, vinblastine and verapamil, but not colchicine, inhibited the binding of 
these photoaffinity drugs to P-glycoprotein [85].
Paclitaxel is an excellent substrate for P-glycoprotein. To study the paclitaxel binding sites 
of P-glycoprotein, several photoaffinity analogs of paclitaxel have been synthesized and 
used [86]. Originally, a photoaffinity analog of paclitaxel bearing tritiated 3H-p-benzoyl-
hydrocinnamoyl (BzDC) was demonstrated to photolabel the mouse mdr1b P-glycoprotein 
(Fig. 1). Subsequently, two other analogs of paclitaxel bearing the tritium-labeled BzDC 
photophore at the 7 and 10 positions of paclitaxel likewise, specifically photoincorporated 
into mouse mdr1b P-glycoprotein [87]. The chemical structure of the 3'-BzDC paclitaxel 
photoaffinity analog is presented in Fig. (1). Web recently synthesized a Taxol photoaffinity 
aPriebe, W.; Przewloka, T.; Fokt, I.; Perez-Soler, R.; Safa, A.R. Amer. Assoc. Cancer Res., 1995, 36, 334 (Abst. 1989).
bGordon, J.D.; Safa, A.R. Amer. Assoc. Cancer Res., 2002, 43, 259 (Abst. 1289).
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analog, N-(p-azido-[3,5-125I]salicyl-3'-N-debenzoyl-Taxol ([125I]NAST), and used it to 
identify and characterize the Taxol binding sites of human P-glycoprotein. Photoaffinity 
labeling of P-glycoprotein in the multidrug resistant KB-V1 human cervical cancer cell line 
with [125I]NAST was inhibited by the MDR-related chemotherapeutic agents Taxol > 
vinblastine > vincristine > actinomycin, but not by doxorubicin. Moreover, P-glycoprotein 
photoaffinity labeling was very effectively inhibited by the MDR modulators PSC 833 > 
cyclosporin A > cis-flupentixol > trans-flupentixol.
A P-glycoprotein-specific [3H]-benzophenone photoaffinity analog of stipiamide, a new 
antibiotic effective in multidrug-resistant cancer cells, showed specific binding to human P-
glycoprotein in the presence of cis-flupentixol, but not with cyclosporin A [88].
B. Photoaffinity Analogs of MDR Modulators
There has been major interest in developing strategies to circumvent MDR in vitro and 
ultimately in resistant tumor cells in patients. It is known that many diverse lipophilic agents 
enhance drug cytotoxicity in MDR cells. These agents possess many structural and chemical 
features common to chemotherapeutic drugs that bind to P-glycoprotein. To examine 
whether compounds known to reverse the MDR phenotype bind directly to P-glycoprotein, 
several photoaffinity analogs of the MDR modulators have been used. We initially used a 
photoaffinity analog of dihydropyridine, [3H]azidopine [75, 89] (Fig. 3), and provided the 
first experimental evidence that [3H]azidopine binds to P-glycoprotein specifically [76, 89]. 
In addition, [3H]azidopine photolabeling was partially blocked by verapamil and diltiazem, 
but was significantly stimulated by excess prenylamine and bepridil [75, 89]. The 
stimulatory effect caused by prenylamine and bepridil may be a positive allosteric effect of 
these agents on [3H]azidopine labeling by binding to a separate site on P-glycoprotein and 
increasing the reversible binding of azidopine and its covalent coupling. The [3H]azidopine 
photolabeling of P-glycoprotein also was inhibited by excess vinblastine > actinomycin D > 
doxorubicin, demonstrating a broad P-glycoprotein drug recognition capacity [75, 89]. 
These data suggest a direct function for P-glycoprotein in the MDR.
To demonstrate directly that P-glycoprotein is a target for verapamil, we initially 
synthesized 3H- and 125I-labeled photoaffinity analogs of verapamil (N-(p-azido-[3, 5-3H] 
benzoyl)aminomethylverapamil ([3H]NAB-VP) and N-(p-azido-3-
[125I]salicyl)aminomethylverapamil ([125I]NAS-VP) [90] (Fig. 3) and showed that they bind 
specifically to this protein [76, 90]. Photoaffinity labeling of P-glycoprotein was inhibited in 
a dose-dependent manner by verapamil, vinblastine [90] and by other calcium channel 
blockers. Photolabeling was also partially inhibited by two of the drugs to which these cells 
are cross resistant, doxorubicin and actinomycin D [90]. Subsequently, Beck and Qian (91) 
using an optically pure photoaffinity analog of verapamil, LU-49888, reported similar 
results.
Since the demonstration of the specific photoaffinity labeling of P-glycoprotein with 
[3H]azidopine and verapamil photoaffinity analogs, several photoaffinity analogs of MDR 
modulators have been shown to specifically bind to P-glycoprotein. These photoaffinity 
analogs are B9209-005, an azido derivative of dexniguldipine [92], [125I]arylazidoprazosin 
([125I]AAP) [93], N-(p-azido-3-125I]iodophenethyl) spiperone ([125I]NAPS) [94] (Fig. 3) 
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and radiolabeled photoaffinity analogs of synthetic isoprenoid [95], cyclosporin A [96], 
forskolin [97] and estramustine [98] (Figs. 3 and 4). Progesterone, [99] the synthetic 
progestin R5020 (promegestone) [80], and corticosterone [100] are also inherently 
photoactivatable and have been shown to bind to P-glycoprotein. Whether these compounds 
label similar or different sites on P-glycoprotein and whether they share closely related or 
separate sites with cytotoxic agents remain to be determined.
The pipecolinate derivative VX-710 (Biricodar) [101, 102] (Fig. 4) has been shown to 
modulate both P-glycoprotein 'as well as MRP functions. It reverses P-glycoprotein-
mediated MDR at concentrations of 0.5–2.5 μM by direct interaction with P-glycoprotein 
and inhibition of its efflux activity [102]. Moreover, at 0.5–5 μM, it restored the sensitivity 
of HL-60/ADR cells known to express MRP1 to the cytotoxic action of doxorubicin, 
etoposide (VP16) and vincristine [101]. Consistent with these results, a photoaffinity analog 
of VX-710, [3H]-(S)-N-[2-oxo-2-(4-azidophenyl)acetyl]piperidine-2-carboxylic acid-1, 7-
bis(3-pyridyl)-4-heptyl ester ([3H]VF-13) [101, 102] specifically photolabeled P-
glycoprotein and MRP1 and VX-710 inhibited this binding in a concentration-dependent 
manner [101, 102]. This is the first photoaffinity analog of MDR modulators that binds to 
both P-glycoprotein [102] and MRP [101]. However, the efficiency of photolabeling of 
MRP by this photoprobe appears to be markedly less than its affinity for P-glycoprotein 
[101]. The combined reversal activity of VX-710 for both P-glycoprotein- and MRP-
mediated MDR mechanisms has made this agent suitable for clinical reversal of MDR [103].
LOCALIZATION OF THE DRUG BINDING SITES OF P-GP
A. Photoaffinity Labeling and Domainal Mapping
Many photoaffinity analogs of cytotoxic agents and MDR modulators have been developed 
in the last decade and have been used to study the drug binding sites of P-glycoprotein. 
However, the actual locations of photoincorporation of only a few P-glycoprotein specific 
analogs have been identified. Moreover, some of these binding sites (domains) have only 
been identified for mouse or Chinese hamster P-glycoprotein, and it is not known whether 
identical sites in human P-glycoprotein are labeled by the photoaffinity analogs. A 
topological model of P-glycoprotein and the approximate locations of its binding sites is 
presented in Fig. (5). Site-directed antibodies raised against various domains of P-
glycoprotein have recognized the binding domains of this protein for [3H]azidopine, 
[125I]AAP and a [125I]-labeled photoactive analog of forskolin [104–106]. [3H]Azidopine 
and [125I]AAP bind within or immediately C-terminal to TM segment 6 and TM segment 12 
[104, 105], and the forskolin photoaffinity analog binds to TM segment 6 or to a region C-
terminal to transmembrane (TM) segment 6 [106]. Recently, Demmer et al. demonstrated 
that labeling of Chinese hamster P-glycoprotein with [125I]iodomycin was restricted to 
amino acid residues 230–312, a region of the protein including TM segment 4, the second 
cytoplasmic loop, and part of TM segment 5 [107]. The results obtained by Wang et al. 
[108] using several fluorescent substrates of P-glycoprotein and P-glycoprotein inhibitors 
also support the assertion of two unequal substrate-binding sites that are allostericaily 
dependent on each other. More recently, using site-directed antibodies to several domains of 
human P-glycoprotein, and domainal mapping of the photoaffinity labeled protein, we found 
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that [125I]NASV, [125I]NAS-VP, [125I]NAPS and azidopine bound to at least one common 
binding domain located within or immediately C-terminal to TM segment 6 of P-
glycoprotein. However, kinetic analysis revealed that vinblastine and cyclosporin A 
competitively interact for the same binding site, while they noncompetitively interact with 
the azidopine-binding site [109, 110]. Therefore, these results suggest that vinblastine and 
azidopine bind to separate binding sites on a common domain. Our data provide direct 
evidence that TM segment 6 is an important domain of P-glycoprotein for recognition of 
some MDR-related drugs and potent P-glycoprotein inhibitors.
Wu et al. [87], using a photoaffinity analog of paclitaxel bearing a 3′-BzDC group (Fig. 1) 
and domainal mapping using site-directed antibodies, showed that amino acid residues 985–
1088 of mouse mdr1b P-glycoprotein interact with this analog. This region includes half of 
the TM segment 12 and terminates just after the Walker A motif in the second nucleotide 
binding fold. Interestingly, another photoaffinity analog of paclitaxel with a 7-DzDC group 
incorporated into amino acid residues 683–760 of mouse P-glycoprotein, a region of the 
protein that includes TM segment 7 and half of TM segment 8 plus the intervening 
extracellular loop [87]. To localize the Taxol binding sites within P-glycoprotein, web 
produced site-directed antipeptideè antisera raised against ten different domains of P-
glycoprotein and used these antibodies to identify peptides containing the Taxol binding 
sites. In these experiments, [125I]NAST photolabeled P-glycoprotein from KB-V1 was 
immunoprecipitated and then digested with S. aureus V8 protease. Maximum digestion with 
this protease revealed four major [125I]NAST-bound peptides, 12 kDa, 10 kDa, 8 kDa and 
6.5 kDa, which were immunoprecipitated using an antibody produced against amino acid 
residues N-terminal to TM segment 3. These peptides all seem to have a short five amino 
acid intercellular sequence in common, which is C-terminal to TM segment 4. Moreover, 
[125I]NAST also bound to another 6.5 kDa peptide, which was immunoprecipitated using an 
antibody produced against amino acid residues C-terminal to TM segment 6. Our data also 
suggest that the 6.5 kDa Taxol binding domain C-terminal to TM segment 6 appears to 
overlap the vinblastine, verapamil, and azidopine-binding domain. These data indicate that 
regions C-terminal to TM segment 4 and TM segment 6 appear to be a putative binding 
pocket for Taxol in human P-glycoprotein. These results compared with those reported by 
Wu et al. [87] as discussed above suggest that either Taxol may bind to different domains in 
mouse mdr1b P-glycoprotein compared to human P-glycoprotein, or that different 
photoaffinity analogs of Taxol may bind to non-identical domains. These results also 
suggest the possibility that different domains of P-glycoprotein may form a three-
dimensional arrangement of the drug binding sites. This idea is consistent with the finding 
that [125I]NAS-VP bound to two major 6.5 and 11 kDa peptides and one minor 12 kDa 
peptide within P-glycoprotein, while kinetic analysis of the binding of [125I]NAS-VP under 
equilibrium conditions to P-glycoprotein-bearing membrane vesicles showed a single high 
affinity binding siteb. These data suggest that spatially, these three [125I]-bound peptides 
may form a single binding site. Based on these results, it is tempting to speculate that (1) the 
orientation of the photoactive group in the drug binding pocket determines which domain of 
P-glycoprotein is labeled, and (2) P-glycoprotein substrates interact with distinct domains of 
the protein as a result of substantial conformational changes in the P-glycoprotein structure. 
In support of this latter hypothesis, different tertiary conformational changes take place upon 
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the addition of MgATP and MgATP-verapamil, an MDR modulator that binds to and is 
actively transported by P-glycoprotein [111].
To evaluate the mechanism(s) of chemosensitization and identify the binding sites of 
dexniguldipine-HCI, Borchers et al. [112] used a tritium-labeled photoaffinity analog of 
dexniguldipine, [3H]B9209-005, and photoaffinity labeled P-glycoprotein in the multidrug 
resistant T-lymphoblastoid cell line CCRF-ADR5000. After digestion with trypsin, the 
tryptic fragments were separated by high-performance liquid chromatography and analyzed 
by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). The MS 
results, corroborated by MALDI-MS of peptides after one step of Edman analysis, identified 
the 7 kDa dexniguldipine-bound, tryptic P-glycoprotein peptide consisting of amino acid 
residues 468–527. This sequence region is flanked by the Walker motifs A and B of the N-
terminal ATP-binding cassette, suggesting direct interaction of dexniguldipine with the 
nucleotide-binding site of P-glycoprotein.
The presence of multiple drug binding sites on P-glycoprotein could potentially account for 
the wide variety of substrates known to interact with this protein. Several pharmacological 
studies measuring ATP hydrolysis and cellular drug accumulation indicate a multiplicity of 
drug interactions with P-glycoprotein [113–115]. Furthermore, our kinetic analysis of the 
binding of vinblastine and azidopine clearly demonstrated that these agents bind to separate 
sites and that cyclosporin A interacts competitively with vinblastine [109], but 
noncompetitively with the azidopine binding site [116]. Similarly, compounds, such as the 
indolizin sulfone SR33557 [114] and the 1, 4-dihydropyridines [116, 117] are able to confer 
allosteric control to the binding site on P-glycoprotein for the cytotoxic substrate vinblastine. 
These results provided direct evidence for multidrug binding sites within P-glycoprotein. 
Kinetic studies by Martin et al. [118] indicate that vinblastine and paclitaxel bind to separate 
sites within the P-glycoprotein structure and that dihydropyridine calcium channel blockers 
bind to a separate site distinct from the vinblastine and paclitaxel bind sites. Similarly, we 
have also confirmed by kinetic analysis that paclitaxel binds to a site different from that of 
vinblastine (Safa and Agresti, unpublished results). Particularly interesting, as shown in Fig. 
(6), we have demonstrated that P-glycoprotein may interact with some of its substrates 
stereoselectively. For instance, cis- and trans-flupentixol can reverse MDR, but cis-
fiupentixol increased the binding of [125I]AAP to P-glycoprotein nine-fold more than trans-
flupentixol [94]. However, both of these MDR reversing agents were potent inhibitors of 
[125I]NAPS [94], [125I]NASV, and [125I]NAS-VP binding to P-glycoprotein (Safa A. R. and 
Agresti M., unpublished data), suggesting their stereoselective effect on [125I]AAP binding 
of P-glycoprotein. Several investigators have extended the multi-binding site model of P-
glycoprotein. Ayesh et al. [113] and Shao et al. [119] proposed two separate binding sites, 
one for P-glycoprotein substrates, such as vinblastine, mefloquine and tamoxifen, and the 
other one for substrates such as verapamil. Similarly, verapamil and nicardipine display 
noncompetitive interaction with P-glycoprotein. In their model, cyclosporin A interacts with 
both sites [119]. A more complex model was proposed using a photoaffinity analog of 1, 4-
dihydropyridine [120]. Several chemosensitizer domains in P-glycoprotein, distinct from the 
Vinca alkaloid-binding site, were found using this photoaffinity probe. Garrigos et al. [121] 
demonstrated that vinblastine and verapamil could bind to P-glycoprotein either on different 
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or overlapping sites. In contrast, vinblastine and progesterone bind to separate sites. 
However, the original report by Fleming et al. [122] suggested that vinblastine and the 
progesterone analog megestrol acetate (MA) may bind to the same site, but MA has a 
stimulatory effect on the binding of azidopine to P-glycoprotein. More recently, Shapiro et 
al. [123] have proposed a more complete view of the drug binding sites of P-glycoprotein. 
Their data support the existence of three drug-binding sites on P-glycoprotein. The H site is 
selective for Hoechst 33342 and colchicine. The R site is selective for rhodamine 123 and 
anthracyclines. The third binding site on P-glycoprotein has a positive allosteric effect on 
drug transport by the H and R sites. As Shapiro et al. [123] concluded, this allosteric site 
appears to be one of the sites of [125I]AAP photolabeling of P-glycoprotein originally 
reported by Safa et al. [93] and it may not be capable of drug transport [123].
We originally reported that progesterone may bind to the [125I]AAP binding site of P-
glycoprotein [93]. The results of Shapiro et al. [123] strongly support the idea that these two 
compounds bind to the third stimulatory allosteric site on P-glycoprotein and exert the same 
effect. The foregoing discussion fayors a multisite model of the P-glycoprotein drug binding 
sites originally proposed by Tamai and Safa [116] and Safa et al. [94], rather than a 
universal site model with broad substrate specificity as proposed by Borgnia et al. [124]. 
Martin et al. [118] employed radioligand-binding techniques to directly characterize drug 
interaction sites on P-glycoprotein and how these multiple sites interact. The drugs used 
were classified either as (1) substrates, which are known to be transported by P-glycoprotein 
(e.g., vinblastine) or (2) modulators, which alter P-glycoprotein function but are not 
themselves transported by the protein (e.g. XR9576). These authors demonstrated that drug 
interactions with P-glycoprotein were either competitive, at a common site, or 
noncompetitive, at distinct sites. Based on these data, they assign a minimum of four drug 
binding sites on P-glycoprotein. These sites fall into two categories: (1) transport sites, at 
which translocation of drug across the membrane can occur, and (2) regulatory sites, which 
alter P-glycoprotein function. However, some modulators interact with P-glycoprotein at a 
transport site rather than a regulatory site. Moreover, both transport and regulatory sites are 
able to switch between high- and low-affinity conformations. Interestingly, the multiple sites 
on P-glycoprotein display complex allosteric interactions through which binding of drug at 
one site switches other sites between high- or low-affinity conformations. Several issues, 
however, have not been well characterized, such as the number of the drug binding sites, 
their proximity and location, whether the sites for the cytotoxic substrates and those for 
modulators are entirely separate, and the manner in which these sites might influence each 
other.
We initially reported high and low affinity-binding sites for vincristine on P-glycoprotein 
[109]. Martin et al. [125] further determined whether substrate-binding sites on the P-
glycoprotein undergo high- and low-affinity conformations in response to signals arising 
from nucleotide hydrolysis to effect active transport by this transporter. These authors used a 
radioligand binding assay to characterize the interaction of [3H]vinblastine with P-
glycoprotein and determine how drug binding site parameters are altered during a catalytic 
cycle of p-glycoprotein. In the absence of nucleotide, they showed that [3H]vinblastine 
interacts with a single class of binding site with high affinity. In the presence of the 
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nonhydrolyzable ATP analog AMP-PNP, the drug binding site was in a low-affinity 
conformation. There was no alteration in the binding capacity, reflecting a complete shift in 
the high-affmity site to a low-affinity form. Their results suggest that alteration of the 
affinity of the vinblastine-binding site involves only one nucleotide-binding domain per 
transport cycle. The binding of ATP provides the signal to instigate this change, while 
release of phosphate post-ATP hydrolysis returns the transporter to its original state to 
complete the cycle.
It has also been proposed that P-glycoprotein substrates, hydrophobic peptides and MDR 
modulators interact with different overlapping regions of a large and flexible binding site, 
which is able to accommodate more than one substrate at a time [126]. However, this model 
does not explain the allosteric interaction of substrates with P-glycoprotein as previously 
discussed. Based on the kinetic analysis of binding of drugs to P-glycoprotein under 
equilibrium conditions, photoaffinity labeling experiments using various photoaffinity 
analogs of the cytotoxic agents and MDR modulators and competition experiments, as well 
as transport studies described above, seven binding sites are proposed for P-glycoprotein, 
which positively or negatively communicate with each other (Fig. 7). These are (1) the 
vinblastine binding site, which is shared with NAPS, verapamil (VP), and cyclosporin A 
(CsA), (2) the Taxoi binding site, (3) the binding site for dihydropyridine calcium channel 
blockers, (4) the binding site for the calcium channel blocker bepridil (BP), prenylamine, 
and megestrol acetate (MA), (5) the flupentixoi binding site, (6) IAAP binding site, and (7) 
the binding site for Hoechst 33342.
B. Analysis of Mutations Affecting the Drug Binding Sites of P-Glycoprotein
Considerable effort has been invested in characterizing drug resistance changes caused by P-
glycoprotein mutations [52, 53, 127–145]. P-glycoprotein mutations that have appeared in 
cultured cells selected for resistance to particular drugs [130–132], and mutations 
incorporated by site-directed mutagenesis have been evaluated [52, 53, 127, 129, 134–145]. 
In many instances, as a result of a particular mutation, resistance to one drug may increase, 
while the resistance to other drugs may either remain the same or change. Mutation in a 
given amino acid may affect the protein's multiple functions, and in some instances, trying 
to correlate changes in drug resistance to altered drug binding can result in unexpected 
results. For instance, Choi et al. [130] demonstrated that the mutation G185 to V185 in 
human P-glycoprotein that arose during selection of colchicine resistant KB-3-1 cells causes 
increased colchicine resistance and decreased vinblastine resistance. However, we reported 
that this mutation causes a decrease in colchicine binding affinity and an increase in 
vinblastine binding affinity of P-glycoprotein in these cells [78].
There has been significant progress in defining the drug binding sites by site directed 
mutagenesis, obtaining cell lines with mutated P-glycoprotein and detecting alterations in 
the transport of a particular compound. The drug-binding sites of P-glycoprotein likely 
consist of residues from multiple TM segments. Mutational analysis has also shown that TM 
segment 5 and TM segment 6 in the N-terminal half, and TM segment 11 and TM segment 
12 in the C-terminal half of P-glycoprotein, have an active role in drug transport and 
substrate specificity [134, 135, 138]. A domain-swapping study using the MDR1-
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glycoporotein and MDR2-P-glycoprotein showed that a domain including TM segment 11-
loop-TM segment 12 is important for drug transport [139]. Moreover, Loo and Clarke [140] 
performed cysteine-scanning mutagenesis of all the predicted TM segments of P-gp (TM 
segments 1–5 and 7–10) and tested them for inhibition by a thiol-reactive substrate 
dibromobimane to identify residues within the drug-binding domain. The results of these 
studies, as well as those from site directed mutagenesis previously reported by these authors 
[140, 141], indicate that the drug-binding domain of P-glycoprotein consists of residues in 
TMs 4, 5, 6, 10, 11, and 12. Loo and Clarke [140] have also utilized cysteine-scanning 
mutagenesis to assess the interactions between the membrane spanning domains of human 
P-glycoprotein, and have proposed a model for the relative positioning of the membrane 
spanning domains of this protein and provide more insights into the drug binding domains of 
this protein. The results indicate that the TM segments 4, 5, and 6 are in proximity to TM 
segment 12, while TM segments 10, 11, and 12 are in proximity to TM segment 6. As 
concluded by these authors, TM segments critical for drug binding must be close to each 
other and exhibit different conformational changes in response to the binding of drug 
substrate. This arrangement supports previous work indicating that TM segments 4–6 and 
10–12 are involved in drug binding [134, 136, 138]. These authors [129] also recently 
demonstrated that a P-glycoprotein deletion mutant (residues 1–379 plus 681–1025) with 
only the TM segments retained the ability to bindrhodamine. To identify the residues 
involved in rhodamine binding, Loo and Clark [129] generated mutants containing a 
cysteine in the predicted TM segments and reacted them with a thiol-reactive analog of 
rhodamine, methanethiosulfonate (MTS)-rhodamine. The activities of mutants in TM 
segments 6, 9, and 12 were significantly protected from inhibition by MTS-rhodamine by 
pretreatment with rhodamine B, indicating that residues in these TM segments contribute to 
the binding of rhodamine dyes. Site-directed mutagenesis analysis of P-glycoprotein, in 
which point mutations in four amino acids clustered within a portion of the protein proposed 
to be located within transmembrane spanning domain 4 of mouse mdr1b P-glycoprotein 
caused complete loss of Taxol resistance due to each of the four mutationsc. These results 
are also supported our data that Taxol binds to regions C-terminal to TM segment 4 and TM 
segment 6 in human P-glycoprotein. Interestingly, deletion of a phenylalanine at amino acid 
residue 335 of P-glycoprotein (located in TM segment 6) has been shown to cause resistance 
to cyclosporin A and SDZ PSC 833 [142]. Furthermore, this mutation caused reduced 
photoaffinity labeling by cylosporin and azidopine [131]. Song and Melera [143] reported 
that actinomycin D resistant Chinese hamster variants expressing Pgpl with mutations in TM 
segments 9 and 6 are independently capable of conferring the same cross-resistance 
phenotype. Furthermore, the TM segment 6 mutations inhibit the ability of cyclosporin A to 
reverse cross-resistance and to block labeling of the protein by [125I]iodoarylazidoprazosin 
(IAAP), whereas the TM segment 9 mutations do not show similar effects. A chimeric 
protein containing both pairs of mutations confers twice the level of resistance to 
actinomycin D than that expected from the sum of the individual mutations, but it cannot be 
labeled to detectable levels with [125I]IAAP. Thus, TM segment 9 represents a site that 
cooperates with TM segment 6 to mediate drug resistance and [125I]IAAP labeling. 
Mutations in mouse mdr1b P-glycoprotein that alter the ability of steroids to act as either 
cGruol, D.J.; King, M.; Bemacki, R.J.; Ojima, I.; Kuehne, M.E. Anier. Assoc. Cancer Res., 2002, 43, 260 (Abst. 1292).
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substrates or inhibitors have been shown to be confined to a small portion of the protein 
within TM segments 4, 5 and 6 [144]. However, the steroid interaction domain does not 
appear to overlap that of the Taxol interaction domain [145].
PHARMACOLOGICAL REVERSAL OF MDR BY P-GLYCOPROTEIN-
SPECIFIC INHIBITORS
The clinical need to circumvent MDR has prompted major interest in searching for 
compounds capable of blocking P-glycoprotein function. A broad range of compounds that 
interact with P-gp and block drug efflux has been reported to reverse the MDR phenotype. 
Initially, Skovsgaard [146] examined the effect of relatively non-cytotoxic N-acetyl-
daunorubicin on the efflux of daunorubicin from resistant and sensitive Ehrlich ascites 
carcinoma cells, and demonstrated that adding this compound significantly increased the 
antitumor activity of daunorubicin in resistant tumors in vivo; however, no change was 
observed in the wild-type sensitive tumors. The impetus for identifying MDR modulators 
came from the work of Tsuruo et al. [147] showing that the calcium channel blocker 
verapamil reverses MDR. It is now known that a wide variety of lipophilic agents enhance 
drug cytotoxicity in MDR cells, possibly through interaction with P-glycoprotein [9, 10, 80, 
81]. Many agents known to reverse MDR have been extensively reviewed [9, 94–96].
Many structurally distinct agents reverse multidrug resistance (MDR) by binding to P-
glycoprotein and inhibiting the efflux of the MDR-related cytotoxic agents. However, the 
precise mechanism of how these agents interact with P-glycoprotein and reverse MDR is not 
well understood. The kinetics of the inhibition of P-glycoprotein is complex [74], and as 
discussed above, some of the drug binding sites can interact synergistically. On the basis of 
these synergies, in principle, P-glycoprotein inhibitors with increased affinity and specificity 
could be developed.
Several methods have been used to identify and assess the modulating effect of P-
glycoprotein-specific MDR modulators. To investigate how the MDR-related cytotoxic 
agents bind to P-glycoprotein and are effluxed, and whether there is a direct relationship 
between MDR reversal and modulator interaction at the level of P-glycoprotein inhibition, 
we have used five approaches including (1) comparing the IC50 value (concentration which 
inhibits the growth of MDR cells by 50%) for a cytotoxic drug in the absence and presence 
of relatively nontoxic concentrations of a modulator and determining “fold-sensitization”, or 
“degree of potentiation” of the MDR modulator, (2) performing drug accumulation studies 
in drug senstive and MDR variants, (3) using photoaffinity analogs of the MDR-related 
cytotoxic agents and modulators, and identifying and characterizing their binding site by 
photoaffinity labeling, proteolytic digestion, and using P-glycoprotem epitope-specific 
antibodies, (4) inhibiting vinblastine, doxorubicin, verapamil and azidopine photolabeling of 
P-glycoprotein by a given MDR modulator, and (5) performing kinetic analysts and 
inhibition of binding of radioactive vinblastine and vincristine to plasma membrane vesicles 
under equilibrium conditions. Using these approaches, we [109] and others [114, 124, 153] 
have found that potent modulators ot relycoprotein interact either competitively or 
allosterically with the cytotoxic drug binding sites of P-glycoprotein and inhibit its function, 
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thereby allowing the cytotoxic agent to accumulate in the MDR cells, inhibit growth, and 
cause cell death.
Understanding of the structural requirements of modulators of P-glycoprotein function 
should aid in the design of potent and specific therapeutic agents. While relative 
lipophilicity, the presence of a basic nitrogen atom and molecular refractivity have been 
suggested to be important factors for efficient interaction of an MDR reversing agent with P-
glycoprotein [154, 155], the structural determinants or pharmacophore of chemically and 
pharmacologically diverse MDR modulators remain largely unknown. However, several 
reports have further defined important features of P-glycoprotein pharmacophore [156–166]. 
Recent structure-activity relationship studies ot P-glycoprotein substrates and modifiers 
indicate that if two substrates are applied simultaneously to P-glycoprotein, the compound 
with the higher potential to form hydrogen bonds generally acts as an inhibitor [159]. 
Moreover, based on this study, partitioning into the lipid membrane is the rate-limiting step 
for the interaction of a substrate with P-glycoprotein, and dissociation of the P-glycoprotein 
substrate complex is determined by the number and strength of the hydrogen bonds formed 
between the substrate and this multidrug transporter.
In support of this idea, Pajeva and Wiese [161] recently proposed a general pharmacophore 
model of P-glycoprotem drugs that is based on a highly diverse data set and relates to the 
verapamil-binding site of the protein. The pharmacophore model consists of two 
hydrophobic points, three hydrogen bond (HB) acceptor points, and one HB donor point. 
These authors concluded that the binding affinity of the drugs depends on the number of the 
pharmacophore points simultaneously involved in the interaction with P-glycoprotein. On 
the basis of their data, they proposed that (1) the verapamil binding site of P-glycoprotein 
has several points that can participate in hydrophobic and HB interactions, and (2) different 
drugs can interact with different receptor points in different binding modes. To have a better 
understanding of pharmacophore of the P-glycoprotein-specific substrates and inhibitors, 
Ekins et al. [164] built 3-dimensional quantitative structure activity relationship (3D-QSAR) 
models that qualitatively rank and predict IC50 values for P-glycoprotein inhibitors. These 
models were derived and tested with data for inhibition of vinblastine accumulation, 
vinblastine binding, digoxin transport, and calcein accumulation. This study predicted 16 
inhibitors of verapamil binding to P-glycoprotein using these models. These inhibition 
results were then used to generate a new pharmacophore that consisted of one hydrogen 
bond acceptor, one ring aromatic feature, and two hydrophobes. The degree of similarity in 
rank ordering prediction by these inhibitor pharmacophore models confirmed that verapamil, 
vinblastine, and digoxin are likely to bind the same or overlapping sites within P-
glycoprotein. Important features on these substrates include multiple hydrophobic and 
hydrogen bond acceptor characteristics, which are widely dispersed and in agreement among 
most of the other inhibitor pharmacophores reported [165]. These 3D-QSAR models will be 
useful for future prediction of likely substrates and inhibitors of P-glycoprotein. Garrigues et 
al. [166] combined affinities and mutual relationships from the changes in P-glycoprotein 
ATPase activity induced by actinomycin D and a series of cyclic peptides and peptide-like 
compounds, used alone or in combination with a molecular modeling approach, and 
superimposed the three-dimensional hydrophobic and polar elements of these molecules. 
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The results of this study made it possible to characterize two different types of 
pharmacophores in the P-glycoprotein, which appear to be composed of several specific 
sites located close together. Furthermore, the results indicate that the binding of drugs to P-
glycoprotein is governed by the distribution of their hydrophobic and polar elements rather 
than by their chemical motifs.
The MDR modulators can be divided into two groups: (1) those which only bind to P-
glycoprotein and block the binding and transport of MDR-related cytotoxic agents, but 
which are not effluxed (e.g., progesterone, XR9576, and LY335979) [167–169], and (2) 
those which block the binding of MDR-related drugs and are also effluxed from MDR cells. 
These latter modulators compete for outward transport of the MDR-related drugs (e.g. 
cyclosporin A, FK-506, azidopine I-NAPS, and ivermectin) [94,116,170,171].
Three generations of P-glycoprotein-specific MDR modulators have been developed. The 
first generation modulators consisted of calcium channel blockers, calmodulin inhibitors, 
cardiovascular drugs, hormonal/steroidal derivatives antibiotics, the cyclosporins, and other 
miscellaneous compounds [9, 94–96]. These compounds were not specifically developed for 
modulation of MDR and had other pharmacological applications. While these compounds 
were substrates for P-glycoprotein, they were relatively weak MDR modulators. 
Furthermore, major toxicities associated with most of these compounds at the required 
concentrations to inhibit P-glycoprotein activity have prevented their widespread clinical use 
[172–175]. The requirement for more specific and potent P-glycoprotein inhibitors as MDR 
modulators has led to the development of second-generation modulators, such as the non-
immunosuppressive cyclosporin D analogue PSC 833 (Valspodar) [176], VX-710 
(Biricodar) [102], the acridone carboxamide derivative GF120918 (GG918) [177] and the 
diketopiperazine derivative XR9051 [178]. Clinical trials have demonstrated some clinical 
benefit from the use of modulators such as PSC 833 [179, 180]. However, VX-710 and PSC 
833 have shown significant enhancement of the pharmacokinetics and toxicity cytotoxic 
agents such as paclitaxel, and doxorubicin, which has necessitated reduction of the cytotoxic 
drug dose when administered with these modulators [181–183]. The third generation MDR 
modulators have been designed because of the need for compounds lacking other 
pharmacological effects, which thereby confer greater selectivity and specificity for P-
glycoprotein. These modulators include LY335979 [168], R101933 [184] and XR9576 
(Tariquidar) [184], which are the more potent and specific P-glycoprotein modulators. Drug 
binding experiments and kinetic analysis have shown that XR9576 inhibits P-glycoprotein 
function by binding at a modulatory site, which is distinct from the site of interaction of P-
glycoprotein substrates [185]. The two sites may be classified as serving modulatory or 
transport functions [185]. Animal studies have shown that XR9576, and LY335979 exhibit 
no significant pharmacokinetic interaction with doxorubicin, etoposide, and paclitaxel in 
animal studies [168, 169, 186, 187]. Therefore, these studies indicate that the development 
of potent and specific P-glycoprotein inhibitors is an important approach to reversing MDR 
in the clinic of co-administered drugs.
Recent studies have used 99mTc-sestamibi, a substrate of P-glycoprotein, as a functional 
imaging agent for the P-glycoprotein-mediated MDR phenotype [188, 189]. Retention of 
99mTc-sestamibi by cells that overexpress P-glycoprotein can be enhanced by the addition 
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of P-glycoprotein inhibitors. Recent reports have shown enhanced sestamibi retention in 
imaged tumors in a subset of patients treated with the third generation P-glycoprotein-
speciflc MDR modulators [73, 191, 192]. These results suggest that potent and selective P-
glycoprotein modulators can increase drug accumulation in P-glycoprotein-expressing 
tumors. As noted above, since these agents exhibit no significant pharmacokinetic 
interaction with the MDR-related chemotherapeutic agents, using third generation P-
glycoprotein inhibitors and properly designed clinical trials, it should be possible to 
determine the contribution of modulators to the reversal of clinical drug resistance.
Several strategies may be used to achieve maximum modulation of P-glycbprotein-related 
MDR in vitro and some of these strategies can be applicable to the clinical reversal of MDR. 
These strategies include: (1) using P-glycoprotein substrate competitive inhibitors (e.g. 
cyclosporin A is a competitive inhibitor of vinblastine binding to P-glycoprotein), (2) using 
substrates of P-glycoprotein that can bind to the protein and allosterically inhibit binding of 
cytotoxic agents (e.g. azidopine is a noncompetitive inhibitor of vinblastine binding to P-
glycoprotein), (3) using a combination of competitive and allosteric inhibitors of P-
glycoprotein, (4) utilizing membrane active agents that disrupt P-glycoprotein interaction 
with membrane lipid (e.g. lipid fluidizers), (5) using cytotoxic drugs that are not transported 
by P-glycoprotein (e.g. morpholinoanthracyclines), (6) utilizing compounds, which down-
regulate P-glycoprotein expression, (7) using agents that prevent P-glycoprotein induction 
(e.g. protein kinase inhibitors), (8) utilizing anti-P-glycoprotein antibodies with MDR 
modulators, (9) modifying the delivery of MDR drugs (e.g. liposome encapsulation), (10) 
using antisense oligonucleotides to prevent P-glycoprotein expression, and (11) taking 
advantage of the use of agents to which MDR cells are collaterally sensitive. The use of two 
modulators with different toxicities may produce an additive or synergistic effect in 
modulating MDR at lower and safer concentrationsd. Simultaneous use of two modulators, 
one acting competitively and the other acting noncompetitively, with the cytotoxic drug for 
binding to P-glycoprotein is an attractive approach, and we have previously shown that 
combinations of two MDR modulators, cyclosporin A and tamoxifen, synergistically 
enhances the cytotoxicity of vinblastine in a P-glycoprotein-containing cell linedd.
Cytotoxic agents, which are not substrates for P-glycoprotein and therefore, unable to be 
effluxed from the MDR cells, have been shown to be effective in both sensitive cells and 
their P-glycoprotein expressing cells [193]. For example, it has been shown that the amino 
group at the C-3' position of doxorubicin is an important determinant of anthracycline 
binding to P-glycoprotein [193, 194]. Hydroxyrubicin, an analog of doxorubicin, which has 
a hydroxyl group at C-3', was shown to have very poor affinity for P-glycoprotein in 
photoaffinity labeling experiments, and increased activity against MDR cells [194]. 
Lampidis et al. [193], using a selected series of analogs in which lipophilicity and/or 
positive charge were altered, found that positively charged anthracyclines are better 
recognized by P-glycoprotein positive cells compared to their natural counterparts, and with 
increasing lipophilicity, charge becomes less important for P-glycoprotein recognition. 
Interestingly, photoaffinity analysis suggested that the highly lipophilic anthracycline 
dSamuels, B.I.; Murray, J.L.; Safa, A.R. Amer. Assoc. Cancer Res., 1990, 31, 361 (Abst. 2138).
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analogs, regardless of charge, prevent [125I]NAS-VP binding to P-glycoprotein. Consistent 
with these results, in MDR cells with a resistance index to doxorubicin of 4, 534, as 
compared to parental cells, almost all of the resistance is circumvented (resistance index = 3) 
with an anthracycline that does not contain a protonatable nitrogen and is highly lipophilic 
(partition coefficient, log p > 1.99). As lipophilicity is increased to log p > 1.99 and nuclear 
binding is decreased, anthracycline localization switches from nuclear to cytoplasmic, which 
most likely indicates a different cytotoxic target and mechanism of action. Cytoplasmically 
localized anthracyclines appear to also distribute to the mitochondria, which suggests these 
organelles as possible new anthracycline targets. In contract, doxorubicin shows no 
mitochondrial localization. These results revealed for the first time that highly lipophilic 
anthracyclines act as “self-modulators” of MDR. As Lampidis et al. [193] noted, a novel 
approach to circumventing P-glycoprotein-mediated MDR, and possibly other mechanisms 
of drug resistance involving nuclear targets, is the use of anthracyclines, which are highly 
lipophilic and localize in the cytoplasm/mitochondria of cancer cells. However, recently it 
has been shown that lipophilic anthracyclines in general are transported by P-glycoprotein 
[195]. Use of drugs that are not transported by P-glycoprotein is an attractive strategy to 
circumvent MDR. For example, a novel paclitaxel analog, 14-hydroxy-10-deacetylbaccatin 
III, IDN5109, which is not transported by P-glycoprotein, has shown a 20- to 30-fold higher 
activity than paclitaxel on MDR cells [196].
CONCLUSIONS
Significant advances have been made in localizing the drug binding sites of P-glycoprotein 
for cytotoxic agents and MDR modulators. Since the discovery that P-glycoprotein was 
labeled with the photoaffinity analogs of vinblastine [18], photoaffinity labeling has evolved 
as one of the most widely used methods for identifying and characterizing the drug-binding 
sites of P-glycoprotein. Moreover, investigation of P-glycoprotein mutants, transport studies, 
and equilibrium binding assays have provided valuable information on drug binding sites of 
this protein and how they interact with each other. However, the molecular architecture of 
the drug-binding sites, their exact locations within the P-glycoprotein molecule, and the total 
number of these sites remain to be determined. Based on P-glycoprotein drug-binding data, 
it can be concluded that multiple sites interact with the cytotoxic agents and 
chemosensitizers. Moreover, while evidence suggests that these drug-binding sites are 
located in TM segments of P-glycoprotein within the lipid bilayer, it is possible that the 
hydrophobic region(s) of the drugs may bind to the TM segments and the hydrophilic 
region(s) may interact close to the cytosolic domains of P-glycoprotein near the TM 
segments [197]. In fact, it has been recently shown that the binding affinities of P-
glycoprotein-related drugs increase as the drug-lipid partition coefficient increases [198], 
suggesting that effective concentrations of the drugs in the membrane are important for 
interacting with P-glycoprotein. Photoaffinity labeled drugs have been useful for identifying 
regions of P-glycoprotein that bind to cytotoxic drugs and chemosensitizers. The 
development of photoaffinity analogs of drugs that contain photoactive groups at different 
moieties may be useful in determining the spatial arrangement of the drug binding sites. 
Ultimately, structural resolution in three dimensions will be required to determine the 
detailed architecture of the drug binding sites. However, the foregoing discussion in this 
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review should aid in understanding the complexity of drug binding sites of the drug 
transporters, and the usefulness of the photoaffinity drugs for identifying MDR-reversing 
agents.
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Fig. (1). 
Structures of photoaffinity analogs of MDR-related drugs known to covalently label P-
glycoprotein: (I) [125I]NASV, (2) [125I]NASC, (3) [3H]NAB-DNR, (4) [125I]NAS-DNR, (5) 
[125I]ASA-Rh123, (6) [125I]ASA-BZ, and (7) [3H]BzDC-paclitaxel.
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Fig. (2). 
(A) Autoradiogram of [125I]NASV photolabeled plasma membranes (20 μg protein) from 
CEM, CEM/VBL100, CEM/VBL1000 and CEM/VBL5000 cells in the absence (lanes 1, 2, 
4 and 6) or presence of 10 μM nonradioactive vinblastine (lanes 3, 5 and 7). (B) 
Autoradiogram of [125I]NASV photoaffinity labeled KB-3-1 (lane 1) and KB-GRC1 
transfectants (KB-3-1 cells transfected with the MDR1 gene) (lanes 2–7), KB-GRC1 
transfectants (8 × 106 cells) were photoaffinity labeled with 50 nM [125I]NASV (50–60 Ci/
mMole) in the absence (lane 2) or presence of 100 μM vinblastine, actinomycin D, 
doxorubicin, colchicine, or methotrexate, respectively (lanes 3–7), and after subjecting to 
SDS-PAGE, the samples were processed for autoradiography.
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Fig. (3). 
Structures of photoaffinity analogs of MDR modulators known to covalently label P-
glycoprotein: (1) [125I]NAS-VP, (2) LU-49888, (3)[3H]azidopme, (4) [3H]B92009-005, (5) 
[125I]AAP and (6) [125I]NAPS.
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Fig. (4). 
Structures of photoaffinity analogs of MDR modulators known to covalently label P-
glycoprotein: (1) cyclosporin aziridine, (2) synthetic isoprenoid, (3) N-solanesyl-N', N'-bis(3, 
4-dimethoxybenzoyl)ethylenediamine, (4) forskolin analogs, (5) estramustine photoaffinity 
analog, and (6) VF-13.
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Fig. (5). 
Topological model of P-glycoprotein and the approximate locations of its drug binding sites. 
The figure shows the structure of P-glycoprotein with twelve transmembrane domains 
(TMDs) predicted by hydrophobicity plot. Domains of the protein that are involved in the 
binding of iodomycin (IDM), [125I]NASV, [125I]NAS-VP, [125I]NAST, [3H]azidopine 
(AZP), 6-o-[[2-[3-(4-azido-3-[125I]iodophenyl) propionamido]ethyl]-carbamyl)forskolin 
(AIPPF), [125I]iodoarylazidoprazosin (IAAP), [3H]-3'-BzDC-paclitaxel, [3H]-7-BzDC-
paclitaxel (dashed lines, amino acid residues 985–1008 are marked). For details, see the text.
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Fig. (6). 
Photoaffinity labeling of P-glycoprotein from SH-SY5Y/VCR cells with [125I]AAP (lane 1) 
and the effects of 100 μM trifluoperazine, chlorpromazine, thioridazine, perphenazine, W-7, 
cis-flupentixol, trans-flupentixol, fluphenazine and fluphenazine N-mustard (lanes 2–10), 
respectively.
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Fig. (7). 
Proposed classification of multiple drug binding sites of P-glycoprotein. Based on the 
kinetic analysis of drug binding to P-glycoprotein under equilibrium conditions and 
photoaffinity labeling using various photoaffinity analogs of the cytotoxic agents and MDR 
modulators as well as competition experiments described in the text, seven binding sites for 
P-glycoprotein are proposed. Arrows indicate positive or negative communication between 
these sites.
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